New Frontiers in the Treatment of Obesity (#33)
Kendra Bence
1
- Pfizer, Inc., Cambridge, MA, United States
- Emerging success of the GLP1R agonist class of therapeutics in obesity treatment will be highlighted.
- The combination of GLP1R agonism with the GIPR mechanism will be discussed.
- Work in progress: CNS-enriched GPCRs with human genetic support for body weight regulation.